About the compound
Engineered IGF-1 analog: 83 residues, an N-terminal 13-residue extension and an E→R substitution at position 3. C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉, MW 9111.4 Da.
IGF-1 LR3 is an engineered analog of human IGF-1 in which the native 70-residue sequence (UniProt P05019) is extended at the N-terminus by the 13-residue sequence MFPAMPLSSLFVN and substituted at residue 3 (E→R). Empirical formula C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉; MW 9111.4 Da. Native IGF-1 disulfides are preserved.
Reconstitution. Solubility is highest in 0.1% acetic acid or in DMSO; bacteriostatic water suffices for most applications. Avoid alkaline buffers (pH > 8) for prolonged exposure.
Stability profile. Lyophilized: stable at room temperature for up to 30 days sealed; long-term storage at -20 °C recommended. Reconstituted material: stable at 2–8 °C for up to 14 days.
Selected primary literature.
- Francis GL et al., 1992, J Mol Endocrinol 8(3):213 — original engineering and structural characterization of the Long R3 IGF-1 analog (preclinical in-vitro receptor-binding study).
What remains uncharacterized: concentration-response relationships in any specific in-vitro model system are not implied here. The literature cited above describes molecular-level observations only.
For research use only. Not for human or animal consumption.



